Cargando…
Apatinib and fractionated stereotactic radiotherapy for the treatment of limited brain metastases from primary lung mucoepidermoid carcinoma: A case report
RATIONALE: Apatinib is a novel anti-angiogenic agent that targets vascular endothelial growth factor receptor-2, thereby inhibiting tumor angiogenesis, and is effective in the treatment of brain metastases (BM) and peritumoral brain edema (PTBE). There are no previous reports of combination therapy...
Autores principales: | Yan, Hongxia, Li, Xiaolu, Peng, Yi, Zhang, Pingping, Zou, Ning, Liu, Xiyou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581043/ https://www.ncbi.nlm.nih.gov/pubmed/33120847 http://dx.doi.org/10.1097/MD.0000000000022925 |
Ejemplares similares
-
Re-irradiation of multiple brain metastases using CyberKnife stereotactic radiotherapy: Case report
por: Zhou, Han, et al.
Publicado: (2021) -
A case report of apatinib in treating osteosarcoma with pulmonary metastases
por: Zhou, Yong, et al.
Publicado: (2017) -
Radiotherapy with apatinib for recurrence of malignant phyllodes tumor of the breast: A case report
por: Wu, Hong, et al.
Publicado: (2020) -
The use of apatinib in treating primary pleural synovial sarcoma: A case report
por: Chen, Sumei, et al.
Publicado: (2019) -
Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report
por: Liu, Qiuxia, et al.
Publicado: (2019)